ArticleBMC cancer2020

Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials.

Ashley M Hopkins et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.